The company's devices, NANOme and NANOus, are designed for aseptic processing, GMP-compliance and quick scale-up
Leon-nanodrugs has established its own lab facilities at the start-up centre for biotechnology (IZB) in Munich.
The new R&D capacities set the stage for completion of product development for LEON’s manufacturing devices and will afterwards be used to showcase the devices and provide process development services to clients using LEON's equipment.
LEON's product platform is built on their proprietary innovative FR-JET Technology that enables a huge efficiency increase in the formulation process of active ingredients into nanodrug carriers such as lipid nanoparticles (LNPs). LEON's devices, NANOme and NANOus, are designed for aseptic processing, GMP-compliance and quick scale-up. NANOme is optimised for small-scale individual patient and clinical trial-size production. NANOus is a fully-automated, aseptic device enabling the LNP-encapsulation of APIs from medium- to large-scale with high throughput using process analytical technology (PAT).
As one of the key biotech hubs in Germany, the IZB provides not only lab facilities, but also an unparalleled environment to foster innovation and growth
Dr Setu Kasera, Head of Science and Engineering, commented: “We are truly excited about moving into the IZB. As one of the key biotech hubs in Germany, the IZB provides not only lab facilities, but also an unparalleled environment to foster innovation and growth. The local proximity to biotech start-ups, academia, VCs and big pharma creates an ecosystem that facilitates networking in and outside of your peer group, setting the stage for future partnerships. We are looking forward to using our new capacities to complete the development of our devices for the market, while we pursue and build on opportunities for collaborations by providing access to our devices and process development services.
“We welcome LEON to our vibrant biotech centre. At IZB, we strive to support companies that bring new technologies and approaches to the biotech industry, and I am confident the resources and network available at the campus will support LEON in their late-stage product development,” added Dr Peter Hanns Zobel, Managing Director IZB.